Literature DB >> 15653257

Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain.

Lindsay M Reynolds1, Susan M Cochran, Brian J Morris, Judith A Pratt, Gavin P Reynolds.   

Abstract

Administration of phencyclidine (PCP) to both humans and animals models the symptoms of schizophrenia. Brain concentrations of N-acetylaspartate (NAA) are reduced in this disease, reflecting neuronal dysfunction. This study investigates the effects in rats of a chronic intermittent regime of PCP on NAA and its precursor N-acetylaspartylglutamate (NAAG) in rat frontal and temporal cortex, hippocampus and striatum, determined by HPLC. We found significant PCP-induced deficits of NAA and NAAG only in the temporal cortex; NAAG was significantly elevated in the hippocampus. These changes closely reflect postmortem findings reported in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653257     DOI: 10.1016/j.schres.2004.02.003

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

Review 1.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

Review 2.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 3.  How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.

Authors:  Xin Wang; António Pinto-Duarte; Terrence J Sejnowski; M Margarita Behrens
Journal:  Antioxid Redox Signal       Date:  2012-10-18       Impact factor: 8.401

Review 4.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

5.  Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy.

Authors:  Juan Bustillo; Matthew P Galloway; Farhad Ghoddoussi; Federico Bolognani; Nora Perrone-Bizzozero
Journal:  Neurochem Int       Date:  2012-04-13       Impact factor: 3.921

6.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

7.  Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine.

Authors:  W Michael Bullock; Federico Bolognani; Paolo Botta; C Fernando Valenzuela; Nora I Perrone-Bizzozero
Journal:  Neurochem Int       Date:  2009-08-03       Impact factor: 3.921

Review 8.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

9.  1H-MRS at 4 tesla in minimally treated early schizophrenia.

Authors:  J R Bustillo; L M Rowland; P Mullins; R Jung; H Chen; C Qualls; R Hammond; W M Brooks; J Lauriello
Journal:  Mol Psychiatry       Date:  2009-11-17       Impact factor: 15.992

10.  In vivo measurements of glutamate, GABA, and NAAG in schizophrenia.

Authors:  Laura M Rowland; Kimberly Kontson; Jeffrey West; Richard A Edden; He Zhu; S Andrea Wijtenburg; Henry H Holcomb; Peter B Barker
Journal:  Schizophr Bull       Date:  2012-10-18       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.